Biotech RadarJobs updated

COMPANY

Evopoint Biosciences

evopointbio.com ↗

Clinical Phase 3

Profile checked Oct 10, 2026

Keywords: Bacterial Infections Cervical Cancer Relapsed/Refractory Peripheral T Cell Lymphoma Pancreatic Cancer Non-hodgkin Lymphoma Peripheral T-cell Lymphoma Advanced Prostate Cancer Squamous Cell Carcinoma of Head and Neck Urothelial Carcinoma Prostate Cancer Small-cell Lung Cancer Non-small Cell Lung Cancer Metastatic Pancreatic Cancer Grade 1 Follicular Lymphoma Grade 2 Follicular Lymphoma Grade 3 Follicular Lymphoma Follicular Lymphoma Grade 3A Pancreatic Carcinoma Ovarian Cancer Lymphoma Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia Metastatic Castrate-Resistant Prostate Cancer mCRPC (Metastatic Castration-resistant Prostate Cancer) Complicated Urinary Tract Infection Including Acute Pyelonephritis Gout XNW5004 XNW4107, Imipenem/Cilastatin XNW28012 XNW29016 XNW4107

21Trials (company is sponsor)

Timeline

  1. Trial start I: Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer source ↗
  2. Trial start Phase 2: Study of XNW5004 Tablets in Advanced Prostate Cancer source ↗
  3. Trial start Phase 2: Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma source ↗
  4. Trial start I: A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor source ↗
  5. Trial start Phase 1/Phase 2: Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma source ↗
  6. Trial start Phase 3: Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy source ↗
  7. Trial start Phase 1/Phase 2: A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment source ↗
  8. Trial start III: A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma source ↗
  9. Trial start Phase 2: To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma source ↗
  10. Trial start Phase 1/Phase 2: Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments source ↗
  11. Trial start Phase 1/Phase 2: Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) source ↗
  12. Trial start Phase 1/Phase 2: Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer source ↗
  13. Trial start Phase 3: Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40) source ↗
  14. Trial start Phase 3: Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) source ↗
  15. Trial start I: To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors source ↗
  16. Trial start Phase 1: Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects source ↗
  17. Trial start Phase 1: To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females. source ↗
  18. Trial start Phase 1: Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function source ↗
  19. Trial start Phase 1: Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin source ↗
  20. Trial start Phase 1: The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject source ↗
  21. Trial start 1: Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 21

RecordTitlePhaseStatusStartPrimary completion
NCT07823049Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic TherapyPhase 3RecruitingJul 8, 2025May 31, 2027 (estimated)
NCT07730515Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell LymphomaPhase 1/Phase 2RecruitingAug 15, 2025Sep 30, 2028 (estimated)
NCT07730580Study of XNW5004 Tablets in Advanced Prostate CancerPhase 2Not yet recruitingJul 13, 2026Dec 31, 2028 (estimated)
NCT06022757Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)Phase 1/Phase 2TerminatedSep 20, 2023Jan 13, 2025 (actual)
NCT07707674Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic CancerINot yet recruitingJul 30, 2026Apr 30, 2028 (estimated)
NCT07545603Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular LymphomaPhase 2RecruitingFeb 14, 2026Dec 31, 2027 (estimated)
NCT06799637Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard TreatmentsPhase 1/Phase 2RecruitingDec 1, 2023Dec 31, 2026 (estimated)
NCT06558513To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced TumorsICompletedAug 3, 2021Aug 30, 2025 (actual)
NCT06776952A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell LymphomaIIIRecruitingApr 10, 20252028-01 (estimated)
NCT07327294A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid TumorINot yet recruitingJan 31, 2026Dec 31, 2027 (estimated)
NCT05204563Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)Phase 3CompletedJul 31, 2022Sep 29, 2024 (actual)
NCT06987500A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard TreatmentPhase 1/Phase 2RecruitingApr 11, 2025Feb 14, 2027 (estimated)
NCT06702995Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate CancerPhase 1/Phase 2RecruitingApr 19, 2023May 13, 2026 (estimated)
NCT06702605To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell LymphomaPhase 2Not yet recruiting2024-112027-01 (estimated)
NCT04802863Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy SubjectsPhase 1CompletedMar 25, 2021May 15, 2021 (actual)
NCT05204368Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)Phase 3Unknown status (ClinicalTrials.gov)Mar 30, 20232025-06 (estimated)
NCT04482569Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/CilastatinPhase 1CompletedJul 10, 2020Feb 28, 2021 (actual)
NCT03901950Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors1CompletedJul 1, 2019Dec 30, 2021 (actual)
NCT04801043To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.Phase 1CompletedMar 2, 2021Oct 30, 2021 (actual)
NCT04040907The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health SubjectPhase 1CompletedNov 13, 2019Jan 20, 2021 (actual)
NCT04787562Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal FunctionPhase 1CompletedFeb 25, 2021Oct 30, 2021 (actual)
Feedback